M&A - Adiumentum Capital Fund I LP

Form Type: SCHEDULE 13D/A

Filing Date: 2025-05-16

Corporate Action: Acquisition

Type: Update

Accession Number: 000110465925050119

Filing Summary: This Amendment No. 2 to Schedule 13D relates to the filing made by Adiumentum Capital Fund I LP regarding its beneficial ownership in common stock of Atara Biotherapeutics, Inc. Adiumentum holds 1,209,395 shares of Common Stock and 160,686 shares of Common Stock issuable upon exercise of Pre-Funded Warrants, representing 19.99% of outstanding shares as of May 16, 2025. On May 14, 2025, Adiumentum agreed to a Registered Offering to purchase an additional 75,572 shares and Pre-Funded Warrants for 227,000 shares at a price of $6.61 per share. The Registered Offering closed on May 16, 2025, at which time all percentage calculations were based on a total of 6,693,146 shares of Common Stock outstanding. The document clarifies ownership limitations and rights associated with the Pre-Funded Warrants, including potential adjustments to the beneficial ownership limit.